Overview

Nosis Bio develops cell-targeted RNA medicines using its Connexa platform, which combines physics-informed deep learning, generative AI, and high-throughput biochemistry to design Targeted Delivery Vehicles for RNA therapeutics. Connexa builds a receptome atlas of the human proteome and identifies over 2,900 targetable cell-specific receptors to reach diverse tissues while reducing systemic toxicity. The company pursues a wholly owned drug pipeline and collaborates with big pharma to apply its platform to high-value indications. Its goal is to deliver precise, safe, re-dosable RNA therapies to hard-to-reach tissues by expanding targetable cell types and advancing preclinical therapeutics toward clinical use.